347 related articles for article (PubMed ID: 17050608)
21. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.
Cristillo AD; Lisziewicz J; He L; Lori F; Galmin L; Trocio JN; Unangst T; Whitman L; Hudacik L; Bakare N; Whitney S; Restrepo S; Suschak J; Ferrari MG; Chung HK; Kalyanaraman VS; Markham P; Pal R
Virology; 2007 Sep; 366(1):197-211. PubMed ID: 17499328
[TBL] [Abstract][Full Text] [Related]
22. Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus.
de Souza AP; Haut LH; Silva R; Ferreira SI; Zanetti CR; Ertl HC; Pinto AR
Vaccine; 2007 Jan; 25(1):109-16. PubMed ID: 16914235
[TBL] [Abstract][Full Text] [Related]
23. [Study on the immunogenicity of HIV-1 gag vaccine].
Jiang WZ; Jin NY; Li ZJ; Zhang LS
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):272-3. PubMed ID: 15193215
[TBL] [Abstract][Full Text] [Related]
24. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
Akahata W; Yang ZY; Nabel GJ
J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
[TBL] [Abstract][Full Text] [Related]
25. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.
Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
J Virol; 2002 Aug; 76(15):7506-17. PubMed ID: 12097563
[TBL] [Abstract][Full Text] [Related]
26. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
[TBL] [Abstract][Full Text] [Related]
27. The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells.
Hovav AH; Panas MW; Osuna CE; Cayabyab MJ; Autissier P; Letvin NL
J Virol; 2007 Dec; 81(23):12793-802. PubMed ID: 17881444
[TBL] [Abstract][Full Text] [Related]
28. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
[TBL] [Abstract][Full Text] [Related]
29. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.
Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788
[TBL] [Abstract][Full Text] [Related]
30. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of DNA vaccine-induced immune responses by a 72-bp element from SV40 enhancer.
Li HS; Liu Y; Li DF; Zhang RR; Tang HL; Zhang YW; Huang W; Liu Y; Peng H; Xu JQ; Hong KX; Shao YM
Chin Med J (Engl); 2007 Mar; 120(6):496-502. PubMed ID: 17439744
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
33. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
[TBL] [Abstract][Full Text] [Related]
34. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
[TBL] [Abstract][Full Text] [Related]
35. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.
Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; Barnfield C; Liljestrom P; Lasarte JJ; Ruiz J; Inchauspe G; Heeney JL
J Infect Dis; 2005 Sep; 192(5):920-9. PubMed ID: 16088843
[TBL] [Abstract][Full Text] [Related]
36. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity.
Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA
Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435
[TBL] [Abstract][Full Text] [Related]
37. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine.
Harrison JM; Bertram EM; Boyle DB; Coupar BE; Ranasinghe C; Ramshaw IA
Vaccine; 2006 Nov; 24(47-48):6867-74. PubMed ID: 17050052
[TBL] [Abstract][Full Text] [Related]
38. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
[TBL] [Abstract][Full Text] [Related]
39. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
[TBL] [Abstract][Full Text] [Related]
40. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
Casimiro DR; Bett AJ; Fu TM; Davies ME; Tang A; Wilson KA; Chen M; Long R; McKelvey T; Chastain M; Gurunathan S; Tartaglia J; Emini EA; Shiver J
J Virol; 2004 Oct; 78(20):11434-8. PubMed ID: 15452269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
